MID-VOLUME · SEX-BALANCED

fexofenadine Side Effects

fexofenadine (also sold as Allegra) sits MID-VOLUME #239 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 69% of sex-coded reports are female (10,792 F / 4,893 M). Demographics and serious-outcome tables follow.

Data updated 2026-05-15

19,831
FAERS reports

FDA Adverse Event Reporting System extract for fexofenadine. Stamp set WATCHLIST · DEATH-MARKED · HOSP-MID. How figures are compiled.

fexofenadine reporting skew - 69% of sex-coded reports are female (10,792 F / 4,893 M). Volume band MID-VOLUME #239 of 524 by FAERS report count; caseload WATCHLIST.

Mid-book FAERS page for fexofenadine (Allegra) (19,831 reports). Signature SEX-BALANCED. Dominant age band on file: 45-64. Educational reference only.

Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

HEADACHE leads 878 of 19,831 reports

HEADACHE
878
FATIGUE
858
NAUSEA
778
PRURITUS
765
EXTRA DOSE ADMINISTERED
700
DIARRHOEA
693
DIZZINESS
648
RASH
605
SOMNOLENCE
597
DYSPNOEA
589
COUGH
555
INSOMNIA
530
PAIN
488
FEELING ABNORMAL
485
MALAISE
451
CONDITION AGGRAVATED
450

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 10,792 (69%)
Male 4,893 (31%)
Unknown 10

Age peak 45-64 (2,846 reports)

0-17 533 (6%)
18-44 2,114 (23%)
45-64 2,846 (31%)
65-74 1,920 (21%)
75+ 1,865 (20%)

FAERS filings rising toward 2025

2004 2025

Reactions in Death Reports

Death appears on 549 reports (2.8% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 171
PNEUMONIA 58
MALIGNANT NEOPLASM PROGRESSION 30
PYREXIA 30
DIARRHOEA 29
PLATELET COUNT DECREASED 25
SEPSIS 25
FALL 22
INTERSTITIAL LUNG DISEASE 22
DYSPNOEA 21
SEPTIC SHOCK 20
HEPATIC FUNCTION ABNORMAL 19
NAUSEA 19
RESPIRATORY FAILURE 19
ACUTE KIDNEY INJURY 17
CARDIAC ARREST 17
CONSTIPATION 16
DECREASED APPETITE 16
PNEUMONIA ASPIRATION 16
ANAEMIA 15

Reactions in Hospitalization Reports

Hospitalization mid-share (2,701, 13.6%). Co-reported reactions:

Reaction Reports
PNEUMONIA 238
NAUSEA 210
DIARRHOEA 206
FATIGUE 183
DYSPNOEA 161
PYREXIA 156
FALL 153
VOMITING 150
PAIN 144
HEADACHE 143
DIZZINESS 133
RASH 131
MALAISE 117
COVID-19 116
COUGH 100
DECREASED APPETITE 100
SINUSITIS 100
URINARY TRACT INFECTION 96
PRURITUS 92
How to read fexofenadine FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-MID)

FAERS holds 19,831 voluntary reports linked to fexofenadine (Allegra), 2004-2025. Death is listed on 549 (2.8%). Hospitalization appears on 2,701 (13.6%). Top co-reported indication: Product Used For Unknown Indication.

Mid-volume extract - treat DEATH-MARKED · HOSP-MID as signal-detection rates next to 69% of sex-coded reports are female (10,792 F / 4,893 M).

Read with fexofenadine

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.